Scientists test 'Living Drug' to reset the immune system in devastating autoimmune conditions
NCT ID NCT06152172
Summary
This early-stage study is testing the safety and initial effects of a personalized cell therapy called KYV-101 in adults with severe autoimmune diseases. The therapy involves collecting a patient's own immune cells, modifying them to target harmful B cells, and reinfusing them. Up to 24 participants with conditions like lupus nephritis, scleroderma, and certain muscle or blood vessel diseases will receive one dose and be followed for two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital of the Universithy of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.